Home Sectors Healthcare Stock Under Review: Illumina (NASDAQ: ILMN)

Stock Under Review: Illumina (NASDAQ: ILMN)

SHARE

Illumina is in the medical diagnostics and research industry and is part of the healthcare sector. The company CEO is Francis A. DeSouza. Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

Previous Intraday Trading Performance:

The ILMN stock showed a previous change of 3.00% with an open at 331.86 and a close of 338.37. It reached an intraday high of 340.40 and a low of 331.18.

Business Wire:  Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019

Liquidity:

The stock has a market cap of $49.7b with 146.9m shares outstanding, of which the float is 143.8m shares. Trading volume reached 1,447,470 shares compared to its average volume of 872,627 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Illumina shares returned 4.56% and in the past 30 trading days it returned 9.97%. Over three months, it changed 10.77%. In one year it has changed 38.00% and within that year its 52-week high was 372.61 and its 52-week low was 226.62. ILMN stock is 49.31% above its 52 Week Low.

Our calculations show a 200 day moving average of 315.61 and a 50 day moving average of 304.91. Currently ILMN stock is trading 7.21% above its 200 day moving average.

Business Wire:  Illumina to Announce First Quarter 2019 Financial Results on Thursday, April 25, 2019

Earnings:

The last annual fiscal EPS for the company was reported at 5.56 that ended on 31st of December 2018, which according to the previous close, that is a PE of 60.86. Based on 9 analyst estimates, the consensus EPS for the next quarter is 1.34. The TTM EPS is 5.72, which comes to a TTM PE of 59.16. Historically, the PE high was 224.30 and the PE low was 38.40. If the stock reached its PE low, that would represent a price of 219.63, which is a decrease of -35.09%.

Base on our calculations, the intrinsic value per share is 134.67, which means it may be overvalued by -151.25%

Indicators to Watch:

Based on the latest filings, there is 2.10% of insider ownership and 138.70% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.18

SeekingAlpha:  Host Hotel Is A 4% Dividend Swan

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 25.39%, return on assets is 13.52%, profit margin is 22.93%, price-to-sales is 18.92 and price-to-book is 13.23.

Company Scores:

All scores are out of six:
 0  :Valuation Score
 3  :Past Performance Score
 5  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.